IKT-702

N/A

Report date: 2026/03/19 16:58:13

Base Information

Drug NameIKT-702

Drug Alias Nameanti-CD3/anti-FAP bispecific T-cell engager-expressing CAR T-cell therapy (Icell Kealex)FAP-TEA-VV-loaded CAR T-cell therapy (Icell Kealex Therapeutics)IKT-702

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody +[5]

Mechanisms of ActionFibroblast activation protein alpha modulatorsT cell surface glycoprotein CD3 modulators

TargetsProlyl endopeptidase FAPT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesIcell Kealex Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesIcell Kealex Therapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A